Daclizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA441

1.1 Daclizumab is recommended as an option for treating multiple sclerosis in adults, only if:

• the person has active relapsing–remitting multiple sclerosis previously treated with disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis (that is, at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI) and

• alemtuzumab is contraindicated or otherwise unsuitable and

• the company provides the drug with the discount agreed in the patient access scheme.

1.2 This guidance is not intended to affect the position of patients whose treatment with daclizumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta441